Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.
Psaty
Bruce M
BM
Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington 98101, USA. psaty@u.washington.edu
Lumley
Thomas
T
D001384:Azetidines / Q000627:therapeutic use*; D015415:Biomarkers; D002986:Clinical Trials as Topic; D017277:Drug Approval; D000069438:Ezetimibe; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use*; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration
D001384:Azetidines; D015415:Biomarkers; D000960:Hypolipidemic Agents; D011804:Quinolines; C483909:torcetrapib; D000069438:Ezetimibe